

PROMOTION RECOMMENDATION
THE UNIVERSITY OF MICHIGAN
MEDICAL SCHOOL
DEPARTMENT OF INTERNAL MEDICINE

Norah L. Henry, M.D., Ph.D., associate professor of internal medicine, with tenure, Department of Internal Medicine, Medical School, is recommended for promotion to professor of internal medicine, with tenure, Department of Internal Medicine, Medical School.

Academic Degrees:

M.D.	2001	Washington University
Ph.D.	1996	Stanford University
B.S.	1991	Louisiana State University

Professional Record:

2019 - present	Associate Professor of Internal Medicine, with tenure, University of Michigan
2016 - 2019	Associate Professor of Internal Medicine, with tenure, University of Utah, Salt Lake City
2014 - 2016	Associate Professor of Internal Medicine, with tenure, University of Michigan
2008 - 2014	Assistant Professor of Internal Medicine, University of Michigan
2007 - 2008	Clinical Lecturer, Department of Internal Medicine, University of Michigan

Summary of Evaluation:

Teaching: Dr. Henry's teaching reflects the breadth of her work as a physician scientist and clinician. It ranges from mentoring medical students, residents, fellows and junior faculty members in their research interest, to the clinical teaching of medical students and house officers. Dr. Henry's commitment to teaching is evidenced by the many trainees, and fellows whom she has mentored in the past several years that have gone on to their own successful careers. She is very committed to this key academic role. In addition to providing research mentorships and teaching in the clinical setting while on inpatient service, she also provides didactic lectures several times per year to the Hematology/Oncology Fellowship program as well as providing updates on the management of breast oncology to the Department of Internal Medicine. Dr. Henry has also taught at national and international conferences, including for the American Society of Clinical Oncology and the American College of Physicians Internal Medicine Annual Meeting.

Research: Dr. Henry's research focuses on understanding and improving breast cancer survivorship, adherence with adjuvant endocrine therapy, and toxicity of therapy related to breast oncology. Her studies have led to new fundamental knowledge of how duloxetine manages pain in patients with aromatase inhibitor-associated musculoskeletal symptoms. She has authored 110 peer-reviewed articles many published in top-tier journals, including the *Journal of*

Clinical Oncology, *Journal of the National Cancer Institute* and *JAMA*. Dr. Henry has an extraordinary track record of obtaining extramural funding. She is currently the principal investigator of an NIH R21 grant: Inflammatory oxylipins and aromatase inhibitor toxicity in breast cancer, and several foundation grants. Evidence of Dr. Henry's international recognition can be seen in her extensive peer-review service for numerous journals and study sections, including for the National Institutes of Health, and her many invitations for extramural presentations. In 2020, she was appointed as the Daniel F. Hayes, M.D. Breast Cancer Research Professor.

Recent and Significant Publications:

Hertz DL, Douglas JA, Kidwell KM, Gersch CL, Desta Z, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM: Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity. *Pharmacogenetics and Genomics*, 31(5), 116-123, 2021.

Hershman DL, Neugut AI, Moseley A, Arnold KB, Gralow JR, Henry NL, Hillyer GC, Ramsey SD, Unger JM: Patient reported outcomes and long-term non-adherence to aromatase inhibitors. *JNCI: Journal of the National Cancer Institute*, djab022, 2021.

Van Poznak CH, Unger JM, Darke AK, Moinpour C, Bagramian RA, Schubert MM, Hansen LK, Floyd JD, Dakhil SR, Lew DL, Wade JL 3rd, Fisch MJ, Henry NL, Hershman DL, Gralow J: Association of osteonecrosis of the jaw with zoledronic acid treatment for bone metastases in patients with cancer. *JAMA Oncology*, 7(2), 246- 254, 2021.

Schnell PM, Lustberg MB, Henry NL: Adverse events and perception of benefit from duloxetine for treating aromatase inhibitor-associated arthralgias. *JNCI Cancer Spectrum*, 5(2), pkab018, 2021.

Wei M, Wang X, Zimmerman DN, Burt LM, Haaland B, Henry NL: Endocrine therapy and radiotherapy use among older women with hormone receptor-positive, clinically node-negative breast cancer. *Breast Cancer Research and Treatment*, 187(1), 287-294, 2021.

Service: Dr. Henry has performed exceptional leadership institutionally, nationally and internationally. At the University of Michigan, she serves as the associate division chief for Clinical Research and the section head of Breast Oncology in the Division of Hematology/Oncology. Additionally, she serves as the co-chair for the Cancer Control and Prevention Clinical Research Team and as the assistant director of Training, Education and Career Development in the Rogel Cancer Center. Nationally, Dr. Henry was elected as a fellow of the American Society of Clinical Oncology and served as the chair of ASCO 2021 Scientific Program Committee. She is an editorial board member for the *Journal of Clinical Oncology* and *Journal of the National Cancer Institute*. Dr. Henry is a reviewer for numerous journals. She has been a grant reviewer for the German Federal Ministry for Research and Education, Cancer Research for the United Kingdom, and Breast Cancer Now. Dr. Henry is renowned for her treatment of patients with breast cancer and her participation in clinical trials for treatment of symptoms when appropriate, and she uses genomics to assess response and side effects to endocrine therapies.

External Reviewers:

Reviewer A: “Dr. Henry’s CV more than speaks for itself in both breadth and quality. She has accumulated over one hundred publications to date, many in high quality oncologic journals and a large percentage of these are first authored investigations. She has had both an interest and commitment to the understanding and management of breast cancer treatments, their toxicities, and patient’s decision making. She has remained focused in her scientific direction and continues to build on that interest from one investigation to the next...I have had the pleasure of speaking at programs along with Dr. Henry, which has allowed me first hand exposure to her presentation skills and her understanding of our field. She has clearly mastered the ability to integrate complex data and provide thoughtful insight on complicated clinical matters. It is a pleasure to support her promotion with this letter. I only hope that I have represented her considerable efforts and achievements as thoroughly as they deserve.”

Reviewer B: “Dr. Henry meets or well-exceeds all criterion for promotion to Professor of Medicine...I personally know by reputation that Dr. Henry is considered an outstanding clinician. Dr. Henry is in the top 1% of all academic researchers for impact and productivity...She is the world’s foremost expert in this area of scholarly activity and is recognized internationally for her work.”

Reviewer C: “Dr. Henry would meet criteria for promotion to Professor at [my institution], and we would be thrilled were she to join our group...Dr. Henry has compiled an impressive CV, with top tier publications in her area of expertise, and has risen to leadership roles for which she has national and international stature. She has been a solid contributor, as well as led many efforts, exemplified by first and last author publications, and a strong track record of mentorship. I look forward to hearing about her accomplishments as a leader at University of Michigan, and a Professor of Medicine, a title which she has truly earned.”

Reviewer D: “Dr. Henry’s area of excellence is as a translational cancer researcher and specifically using new pre-clinical discoveries as the basis for novel investigator initiated trials. I cannot think of better words to describe Dr. Henry’s professional body of work. In the time she has been a faculty member at the University of Michigan and the University of Utah, she has gained a steadfast and strong reputation and expertise in the field of breast cancer clinical research at both the national and international levels...She has led an amazing amount of clinical trials. She has authored numerous high impact publications in the field of breast cancer clinical research and has established herself as an innovative and cutting edge translational researcher, especially in the field of using genomics to assess response and side effects to endocrine therapies.”


Reviewer E: “It is rare to have the opportunity to review an applicant so well rounded and overtly qualified for promotion as Dr. Henry. She is a true academic ‘triple threat’ with demonstrated excellence across all three missions. She is quite simply an outstanding clinician and researcher, and is a wonderful person with whom to interact...I hold the highest regard for Dr. Norah Lynn Henry. She has the knowledge base and personality traits to succeed in whatever endeavor she pursues. She has already made a major impact on the cancer community and will continue to do so for the foreseeable future.”

Reviewer F: “Over the last decade she has been highly successful in obtaining multiple peer-reviewed grants, including three R01 grants, a R21 grant, funding from the V Foundation for

Cancer Research, and the Hope Foundation Career Engagement award. She has developed and conducted a number of investigator-initiated clinical trials and has served as PI or Co-[]investigator for several consortium projects that are based on interdisciplinary partnerships...I have also had multiple opportunities to share the podium with Dr. Henry during national meetings and have found her presentations to be well thought-out and intellectually stimulating. On a personal note, Dr. Henry is a very pleasant and humble individual. In summary, Dr. Norah Henry is a very committed clinical researcher and educator who is dedicated to academic breast oncology. I am confident that she will continue to produce impactful research and train successful mentees. Her accomplishments justify consideration for appointment to Professor on the tenure track, and I enthusiastically support her application for promotion.”

Summary of Recommendation:

Dr. Henry is nationally and internationally recognized as an expert in the area of breast cancer clinical research, specifically in adjuvant endocrine therapy and toxicity of therapy related to breast cancer oncology. She is a committed teacher and mentor and is active in service at both the institutional and extramural levels. I am pleased to recommend Norah L. Henry, M.D., Ph.D. for promotion to professor, with tenure, in the Department of Internal Medicine, Medical School.



Marschall S. Runge, M.D., Ph.D.
Executive Vice President for Medical Affairs
Dean, Medical School

May 2022